In a phase II clinical trial in the recruiting stage, 16 patients with HER2-positive breast cancer of different stages will receive a DNA vaccine encoding IGFBP2, HER2, and IGF1R together with paclitaxel and HER2-targeted monoclonal antibody treatment as neoadjuvant therapy before the surgical removal of the tumor. This evidence concerns the gene ERBB2 and breast carcinoma.